Top Cannabis Investment News, Member Posts, Cannabis Investment Daily Indices and more!

1yr ago Cannabis greenmarketreport Views: 291

-

The Daily Hit is a recap of the top financial news stories for February 2, 2023.

On the Site

MedMen on the Brink of Collapse

MedMen (OTC: MMNFF) is at the edge of capitulation after new financial statements on Thursday show the once-mighty MSO may not be able crawl out of the hole of debt it dug for itself. The company reported that it is more $137 million in debt, with $15 million cash and equivalents on the books. Read more here.

Curaleaf Employees Asks for Class Action Status Over Stolen Tips

Four dispensary employees asked an Illinois judge to certify a class in their suit against Curaleaf Holdings (CSE: CURA) (OTCQX: CURLF) alleging that MSO store managers pocketed more than $125,000 in stolen tip jar money meant for workers. Read more here.

Irwin Naturals Raises $40 Million for Clinic Expansion

Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) reported that it had secured a credit facility as of February 1, 2023, with its existing commercial lender for up to $60 million with $40 million of it currently committed. Irwin Naturals said this money will help it to accelerate its roll-up and be a significant player in the world of psychedelic mental health clinics. Read more here.

Missouri’s Recreational Market Begins to Take Shape

Adult-use cannabis sales will be allowed to start on Monday in Missouri, led by medical marijuana operators that receive approval from the state by then. Lisa Cox, the state health department’s communication director, told Green Market Report that the “vast majority” of licensed medical cannabis facilities applied to participate in the adult-use program, but the approval process is just getting under way. Read more here.

In Other News

Celadon Pharmaceuticals

Celadon Pharmaceuticals Plc, a U.K. pharmaceutical company, gained MHRA registration for Good Manufacturing Practice manufacture of their high-THC cannabis active pharmaceutical ingredient. It is a worldwide industry leader with multibillion dollar acquisition potential. According to a spokesperson of the company, this is the first registration of a U.K. pharmaceutical facility for high delta-9-tetrahydrocannabinol cannabis API since the legalization of medical cannabis in the year 2018 in the U.K. Read more here.

Oregon Liquor and Cannabis Commission

Steve Marks, the longtime director of the Oregon Liquor and Cannabis Commission, told staff Wednesday that he will be resigning at the request of Gov. Tina Kotek. The resignation, first reported by Willamette Week, is not yet final, according to OLCC spokesperson Mark Pettinger. He said Marks had acknowledged the rumors swirling around the agency at a management meeting Wednesday, telling staff that details remained to be worked out. Read more here.

Daily Hit: February 2, 2023 on Green Market Report.


Today's Cannabis Investment Headlines:

Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.